Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD9056 formulation Phase III · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 50 or 400 mg AZD9056, Test formulation |
| 2 | EXPERIMENTAL | 50 or 400 mg AZD9056, Reference formulation |
| Name | Type | Description |
|---|---|---|
| AZD9056 formulation Phase III 50 mg (T) | DRUG | Given as 50 mg tablet (T) |
| AZD9056 formulation Phase IIb 50 mg (R) | DRUG | Given as 50 mg tablet (R) |
| AZD9056 formulation Phase III 200 mg (T) | DRUG | Given as 400 mg (2 x 200 mg tablet (T)) |
| AZD9056 formulation Phase IIb 200mg (R) | DRUG | Given as 400 mg (2 x 200 mg tablet (R)) |
Inclusion Criteria: * Provision of informed consent prior to any study-specific procedures * Healthy Volunteers, Females should not be of childbearing potential * BMI between 18 and 30 kg/m2 Exclusion Criteria: * Clinically significant ECG abnormality suggestive of underlying cardiovascular disea...
AZD9056 formulation Phase III is a small molecule drug being developed by AstraZeneca PLC. It is currently in Phase 1 clinical development. The drug is being studied in healthy volunteers, and the therapeutic area is classified as Other. It is an investigational drug and has not been approved by regulatory authorities.
AZD9056 formulation Phase III is being studied for use in healthy volunteers. The drug is in Phase 1 clinical development, and the current clinical trial is a relative bioavailability study. The drug is not approved for any medical condition and is still in the early stages of clinical investigation.
AZD9056 formulation Phase III is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The drug is currently in Phase 1 clinical development, and the company is conducting trials to evaluate its properties in healthy volunteers.
AZD9056 formulation Phase III is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. There is one completed Phase 1 trial, and no active trials are currently ongoing. The drug is being studied in healthy volunteers.
AZD9056 formulation Phase III has one completed clinical trial, NCT00908934, titled 'AZD9056 Relative Bioavailability Study'. This Phase 1 trial enrolled 24 healthy volunteers in the United Kingdom. The study was controlled and randomized, and it has been completed. No active trials are currently listed.
AZD9056 formulation Phase III is a specific formulation of the drug AZD9056, as indicated by its name. The drug is being developed by AstraZeneca PLC and is currently in Phase 1 clinical development. The clinical trial NCT00908934 is studying this formulation in healthy volunteers.